Possible predictive markers related to micro-metastasis in breast cancer patients

Oncology Reports

Volumn 15, Issue 5, 2006, Pages 1217-1223

  Zhu, Li ^a,b   Loo, Wings T Y ^a   Cheng, Carter W N ^a   Chow, Louis W C ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Blood; Bone marrow; Magnetic activated cell separation; Quantitative RT PCR; Sentinel lymph node

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; RNA; TUMOR MARKER; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ARTICLE; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; UPREGULATION;

BREAST NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; RNA, NEOPLASM; SENTINEL LYMPH NODE BIOPSY; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33744992723     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.5.1217     Document Type: Article

References (66)

1. Pantel K, Cote RJ and Fodstad Ø: Detection and clinical importance of micrometastic disease. J Natl Cancer Inst 91: 1113-1124, 1999. (Pubitemid 29330549)
2. Hellman S: Stopping metastases at their source. N Engl J Med 337: 996-997, 1997.
3. Sidransky D: Nucleic acid-based methods for the detection of cancer. Science 278: 1054-1059, 1997.
4. Solakoglu O, Maierhofer C, Lahr G, et al: Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA 99: 2246-2251, 2002. (Pubitemid 34169046)
5. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH and Riethmuller G: Genetic heterogeneity of single disseminated tumor cells in minimal residual cancer. Lancet 360: 683-689, 2002. (Pubitemid 35232337)
6. Schmidt-Kittler O, Ragg T, Daskalakis A, et al: From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100: 7737-7742, 2003. (Pubitemid 36760039)
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGurie WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
8. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
9. Hynes NE and Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184, 1994.
10. Revillion F, Bonneterre J and Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791-808, 1998. (Pubitemid 28248487)
11. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S and Hayes DF: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518-2525, 1997. (Pubitemid 27289880)
12. Berns EM, Foekens JA, van Staveren IL, van Putten WL, De Koning HY, Portengen H and Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11-18, 1995.
13. Archer SG, Eliopoulos A, Spandidos D, et al: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259-1266, 1995.
14. Carlomagno C, Perrone F, Gallo C, et al: C-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702-2708, 1996. (Pubitemid 26329655)
15. Lipton A, Ali SM, Leitzel K, et al: Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21: 1967-1972, 2003. (Pubitemid 46606385)
16. Lim HY, Joo HJ, Choi JH, et al: Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 6: 519-525, 2000. (Pubitemid 30111473)
17. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H and Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998. (Pubitemid 28521147)
18. Mohammed SI, Knapp DW, Bostwick DG, et al: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59: 5647-5650, 1999.
19. Chan G, Boyle JO, Yang EK, et al: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59: 991-994, 1999. (Pubitemid 29135955)
20. Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90: 455-460, 1998. (Pubitemid 28160637)
21. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I and Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55: 429-434, 2002. (Pubitemid 34620779)
22. Relf M, Le Jeune S, Scott PA, et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor b-1, platelet-derived endothelial growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963-969, 1997. (Pubitemid 27098025)
23. Eppenberger U, Kueng W, Schlaeppi JM, et al: Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16: 3129-3136, 1998. (Pubitemid 28417436)
24. Beck L and D'Amore PA: Vascular development: cellular and molecular regulation. FASEB J 11: 365-373, 1997.
25. Shweiki D, Itin A, Soffer D and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
26. Fredriksson L, Li H and Eriksson U: The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev Aug 15: 197-204, 2004.
27. Coltrera MD, Wang J, Porter PL and Gown AM: Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 15: 2703-2708, 1995.
28. Martell M, Gomez J, Esteban JI, et al: High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol 37: 327-332, 1999. (Pubitemid 29056398)
29. Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R and Vidaud M: Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer 78: 661-666, 1998. (Pubitemid 28507194)
30. Hu XC, Wang Y, Shi DR, Loo WTY and Chow LWC: Immunomagnetic tumor cell enrichment is promising in detecting circulating breast cancer cells. Oncology 64: 160-165, 2003. (Pubitemid 36173382)
31. -ΔΔCt method. Method 25: 402-408, 2001.
32. Redding WH, Coombes RC, Monaghan P, et al: Detection of micrometastases in patients with primary breast cancer. Lancet ii: 1271-1274, 1983. (Pubitemid 14242918)
33. Harbeck N, Untch M, Pache L and Eiermann W: Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 69: 566-571, 1994. (Pubitemid 24076481)
34. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U and Coombes RC: Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 354: 197-202, 1999. (Pubitemid 29329158)
35. Braun S, Pantel K, Muller P, et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med 342: 525-533, 2000. (Pubitemid 30117892)
36. Solomayer EF, Diel IJ, Salanti G, Hahn M, Gollan C, Schutz F and Bastert G: Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 7: 4102-4108, 2001. (Pubitemid 34044634)
37. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N and Jager W: Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 19: 3669-3674, 2001. (Pubitemid 32786279)
38. Gerber B, Krause A, Muller H, et al: Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 19: 960-971, 2001. (Pubitemid 32176270)
39. Wiedswang G, Borgen E, Karesen R, et al: Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21: 3469-3478, 2003. (Pubitemid 46594079)
40. Naume B, Borgen E, Nesland JM, et al: Increased sensitivity for detection of micrometastases in bone marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer 78: 556-560, 1998. (Pubitemid 28507177)
41. Krag DN, Ashikaga T, Moss TJ, et al: Breast cancer cells in the blood: A pilot study. Breast J 5: 354-358, 1999.
42. Beitsch PD and Clifford E: Detection of carcinoma cells in the blood of breast cancer patients. Am J Surg 180: 446-448, 2000.
43. Kraeft SK, Sutherland R, Gravelin L, et al: Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res 6: 434-442, 2000. (Pubitemid 30111461)
44. Kruger W, Datta C, Badbaran A, et al: Immunomagnetic tumor cell selection-implications for the detection of disseminated cancer cells. Transfusion 40: 1489-1493, 2000. (Pubitemid 32048535)
45. Kim SJ, Ikeda N, Shiba E, Takamura Y and Noguchi S: Detection of breast cancer micrometastases in peripheral blood using immunomagnetic separation and immunocytochemistry. Breast Cancer 8: 63-69, 2001.
46. Weihrauch MR, Skibowski E, Draube A, Geller A, Tesch H, Diehl V and Bohlen H: Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies. Clin Exp Metastasis 19: 617-621, 2002. (Pubitemid 35454572)
47. Witzig TE, Bossy B, Kimlinger T, et al: Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 8: 1085-1091, 2002. (Pubitemid 34517644)
48. Turner RR, Ollila DW, Krasne DL and Giuliano AE: Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 226: 271-278, 1997. (Pubitemid 28070919)
49. Turner RR, Ollila DW, Stern S and Giuliano AE: Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Pathol 23: 263-267, 1999. (Pubitemid 29117560)
50. Czerniecki BJ, Scheff AM, Callans LS, et al: Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 85: 1098-1103, 1999. (Pubitemid 29115589)
51. Schreiber RH, Pendas S, Ku NN, et al: Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann Surg Oncol 6: 95-101, 1999. (Pubitemid 29077494)
52. Liu LH, Siziopikou KP, Gabram S and McClatchey KD: Evaluation of axillary sentinel lymph node biopsy by immunohistochemistry and multilevel sectioning in patients with breast carcinoma. Arch Pathol Lab Med 124: 1670-1673, 2000.
53. Canalis E and Rydziel S: Platelet-derived growth factor and the skeleton. In: Principles of Bone Biology. Bilezikian JB, Raisz LG and Rodan GA (eds). San Diego, Academic Press, pp619-626, 1996.
54. Yi B, Williams PJ, Niewolna M, Wang Y and Yoneda T: Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62: 917-923, 2002. (Pubitemid 34126973)
55. Ariad S, Seymour L and Bezwoda WR: Platelet-derived growth factor in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat 20: 11-17, 1991.
56. Seymour L, Dajee D and Berzwoda WR: Tissue platelet derived growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26: 247-252, 1993. (Pubitemid 23304240)
57. Seymour L and Berzwoda WR: Positive immunostaining for platelet-derived growth factor is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Treat 32: 229-233, 1994. (Pubitemid 24313348)
58. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G and Pantel K: ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61: 1890-1895, 2001. (Pubitemid 32692004)
59. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997. (Pubitemid 27076453)
60. Toi M, Inada K, Suzuki H and Tominaga T: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36: 193-204, 1995.
61. Gasparini G, Toi M, Gion M, et al: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89: 139-147, 1997. (Pubitemid 27034790)
62. Gasparini G, Toi M, Miceli R, et al: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 5: 101-111, 1999. (Pubitemid 29169299)
63. Linderholm B, Tavelin B, Grankvist K and Henriksson R: Vascular endothelial growth factor is of high prognostic value in nodenegative breast carcinoma. J Clin Oncol 16: 3121-3128, 1998. (Pubitemid 28417435)
64. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B and Henriksson R: Correlation of vascular endothelial growth factor content with recurrences, survival and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18: 1423-1431, 2000. (Pubitemid 30205387)
65. Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S and Sonoo H: Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 90: 977-981, 1999. (Pubitemid 29500437)
66. Schrey MP and Patel K: Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72: 1412-1419, 1995.